17 completed, 1 terminated. 18 Phase 3.
By phase and status
Follow Simeprevir: new trials by email Literature Review of Simeprevir trials Research Report on Simeprevir
Trials (filtered) newest first · largest first
All 18 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC Sofosbuvir, Ribavirin, Simeprevir - Hepatitis C, Chronic, Hepatocellular Carcinoma Phase 3 Completed 150 2016-03-01 2026-04-13
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis Simeprivir (SMV), Sofosbuvir (SOF), Ribavirin (RBV) - Hepatitis C Phase 3 Terminated 9 2015-05-01 2021-09-13
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection Simeprevir, Sofosbuvir - Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C Phase 3 Completed 40 2015-01-01 2016-11-17
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis Simeprevir, Sofosbuvir - Hepatitis C Virus Infection Phase 3 Completed 103 2014-04-01 2016-04-04
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis Simeprevir, Sofosbuvir - Hepatitis C Virus Infection Phase 3 Completed 310 2014-04-01 2016-04-12
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection TMC435, Pegylated interferon alfa-2a (PegIFNα-2a), Ribavirin (RBV) - Hepatitis C, Chronic, Infection Phase 3 Completed 232 2013-09-01 2016-09-21
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients TMC435, Peginterferon-alpha (PegIFNα-2a), Ribavirin (RBV) - Hepatitis C, Chronic Phase 3 Completed 457 2012-11-01 2015-08-13
A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients TMC435 - Hepatitis C Phase 3 Completed 107 2012-03-27 2017-07-07
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy TMC435, TVR - Hepatitis C Phase 3 Completed 771 2012-02-01 2016-04-26
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study TMC435 - Hepatitis C Phase 3 Completed 142 2011-12-01 2016-04-04
A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 TMC435, Pegylated interferon alpha-2a, Ribavirin - Hepatitis C Virus Genotype-1 Phase 3 Completed 109 2011-10-01 2014-10-29
A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection TMC435, Peginterferon alfa-2b (pegIFN alfa-2b), Ribavirin (RBV) - Hepatitis C, Chronic Phase 3 Completed 79 2011-05-01 2014-05-05
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants Placebo, TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b) - Hepatitis C Phase 3 Completed 393 2011-03-01 2014-06-13
A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients Placebo, TMC435, Peginterferon alfa-2a (pegIFN alfa-2a) - Hepatitis C, Chronic Phase 3 Completed 183 2011-02-01 2014-01-17
A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy TMC435, Peginterferon alfa-2a (PegIFNα-2a ), Ribavirin (RBV) - Hepatitis C, Chronic Phase 3 Completed 106 2011-02-01 2014-01-24
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients Placebo, TMC435, Peginterferon alpha-2a (PegIFN alpha-2a) - Hepatitis C Phase 3 Completed 395 2011-02-01 2014-06-04
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a) - Hepatitis C Phase 3 Completed 394 2011-02-01 2014-04-23
A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy TMC435, Pegylated interferon (pegIFN alpha-2a), Ribavirin (RBV) - Hepatitis C, Chronic Phase 3 Completed 49 2011-01-01 2014-02-04
Conditions studied Hepatitis C (13) · Hepatitis C, Chronic (8) · Fibrosis (2) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Hepatocellular (1) · Infections (1)
Sponsors Janssen R&D Ireland (9) · Janssen Pharmaceutical K.K. (4) · Janssen Infectious Diseases BVBA (2) · Janssen-Cilag International NV (1) · National Hepatology & Tropical Medicine Research Institute (1) · University of Colorado, Denver (1)
Countries United States (9) · Spain (8) · Canada (7) · France (7) · Germany (7) · Belgium (6) · Puerto Rico (6) · United Kingdom (6) · Austria (5) · Australia (4) · Japan (4) · Poland (4) · Portugal (4) · Argentina (3) · Brazil (3)
Top investigators Aisha El Sharkawy, MD (1) · Amanda Wieland, MD (1) · Amr Maged (1) · Gamal Esmat, MD. (1) · Mai Mehrez, MD. (1) · Mohamed Hassany, MD (1)
Results publications PMID 25445400 , PMID 17593061 , PMID 17635375 , PMID 17850410 , PMID 18266997 , PMID 19053983 , PMID 24602923 , PMID 24907224 , PMID 24907225 , PMID 25192745 , PMID 25482330 , PMID 25596313 , PMID 26743093 , PMID 26753774 , PMID 26799692 , PMID 27428331 , PMID 27896822 , PMID 28056030 , PMID 28577353 , PMID 29727383 , PMID 8213790 , PMID 9346731
NIH funding 2014 (1) , UL1TR001082 (1)